Omeros (OMER) said Thursday that results from a statistical analysis of narsoplimab, its monoclonal antibody to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, showed robustness of the previously reported primary endpoint analysis.
The company said that newly completed sensitivity analyses confirm the survival benefit of narsoplimab in patients with hematopoietic stem cell TA-TMA. The results support the previously reported findings that narsoplimab-treated patients had a significant reduction in the risk of mortality.
Omeros added that it plans to resubmit the biologics license application for narsoplimab to the US Food and Drug Administration later this quarter, aiming for it to become the first approved treatment for TA-TMA, with a European submission planned for mid-year.
Omeros shares were higher 2% in recent trading.
Price: 9.08, Change: +0.18, Percent Change: +2.02
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。